how InvestingPro spotted Latigo’s 48% decline before it happened

On August 29, 2026, InvestingPro's Fair Value models identified Latigo Biotherapeutics, Inc.'s (NASDAQ:LTGO) stock as significantly overvalued. Despite multiple Wall Street analysts issuing buy ratings due to the healthcare stock's potential as a pain drug, the Fair Value analysis revealed a stark contrast to the stock's intrinsic worth.

Latigo Biotherapeutics operated within the healthcare sector and had a market capitalization of $835 million. When flagged by InvestingPro, the company was experiencing deeply negative fundamentals, with an EBITDA of -$112.16 million and EPS of -$116.74. However, the stock had already surged 20.66% in August, reaching $24.23—a price that, according to Fair Value analysis, was approximately 42% above the stock's intrinsic value of $14.04.

As the fair value model predicted, Latigo Biotherapeutics' stock declined in the subsequent months, with significant drops in September (-24%), October (-16%), and November (-10%). By early November, the stock had reached $12.60, marking a 48% decline from its peak. This decline closely matched the predicted overvaluation, demonstrating the effectiveness of InvestingPro's Fair Value analysis in protecting investors from overpaying even when analyst sentiment appeared bullish.

Despite the wave of buy ratings from major firms such as Goldman Sachs, Jefferies, and Guggenheim, all citing Latigo Biotherapeutics' potential in pain drug development, the contrarian call proved valuable. InvestingPro's Fair Value models determined that the stock price had risen too far ahead of its fundamentals. Currently, the company continues to report negative EBITDA of -$110.38 million, with EPS improving to -$10.41.

Investors interested in replicating this type of analysis can access Fair Value data for thousands of stocks through InvestingPro, along with other valuable tools such as AI-powered stock picks, comprehensive financial health scores, and real-time alerts on market opportunities.